Orexo US, Inc.

What Orexo US, Inc. does

Orexo US, Inc. is the wholly-owned United States subsidiary of Orexo AB (publ), a Swedish pharmaceutical company publicly traded on Nasdaq Stockholm (ticker: ORX). The US entity is headquartered in Parsippany, New Jersey with approximately 25 employees, and its stated mission is to bring innovative treatment solutions to US patients with severe diseases and life-threatening conditions requiring rescue medications. The subsidiary operates as the US commercial and corporate-presence arm of the parent group, with no independent R&D footprint disclosed.

The company's core technology is AmorphOX®, a proprietary drug delivery platform developed and owned by parent Orexo AB (publ) that improves the bioavailability and chemical stability of both large and small molecule APIs. AmorphOX® is positioned as a formulation science platform enabling new routes of administration, manufacturing processes, and distribution approaches, and is described as a differentiator that the US entity inherits rather than develops independently. No specific commercial product lines, branded assets, or pipeline candidates attributable to the US subsidiary are disclosed in the source material.

The business model is that of a strategic operating subsidiary executing US-market commercialization, medical affairs, and market access activities on behalf of the parent group's portfolio. The US leadership team comprises a Chief Medical Officer (Edward Kim, MD, since October 2022), a Senior Vice President of Product and Portfolio Strategy (Lisa M. Moore, since May 2024, with prior opioid rescue commercial leadership at Emergent BioSolutions), and a Senior Vice President of Market Access & Government Affairs (Rich Murphy, since August 2013, with 30+ years at Bayer, Merck, and other multinationals). No pricing model, revenue mechanics, distribution channels, payer mix, or customer concentration data is publicly disclosed, and no M&A, partnership, or funding activity specific to the US entity is on record.

Name

Orexo US, Inc.

Legal name

Orexo US, Inc.

Website

https://us.orexo.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Orexo US, Inc. is the wholly-owned US subsidiary of Sweden-based Orexo AB (publ), operating a 25-person commercial, medical affairs, and market access organization in Parsippany, NJ to bring the parent's AmorphOX®-based severe-disease and rescue medications to US patients.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Drug delivery technology
• Pharmaceutical development
• Rescue medications
• Severe disease treatments
• Bioavailability enhancement

Headquarters

HQ city

Parsippany

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Operations, Technology or R&D, Others

Core offering

Orexo US, Inc. is the U.S. subsidiary of Orexo AB (publ), a Swedish pharmaceutical company. The company develops and commercializes pharmaceutical products based on its proprietary AmorphOX® drug delivery technology, focused on treatments for severe diseases and life-saving rescue medications. Operating from Parsippany, New Jersey, the unit leads U.S. market entry, product strategy, and market access for Orexo's specialty pharmaceutical portfolio.

Product overview

Orexo US, Inc. is a pharmaceutical company that operates as the US subsidiary of Orexo AB (publ). The company's core offering centers on its proprietary AmorphOX® drug delivery technology, which is designed to improve bioavailability and stability for pharmaceutical applications. The company focuses on developing treatments for severe diseases and life-saving rescue medications.

Differentiator

Problem solved

Functional benefit

Products and services

• AmorphOX® Drug Delivery Technology Platform A proprietary, powder-based drug delivery technology platform used to develop pharmaceutical products with improved stability, solubility, and bioavailability. It underpins Orexo's pipeline of treatments for severe diseases and life-saving rescue medications marketed through the U.S. subsidiary.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves4 records

Expansion highlights3 records

Direct peers

• Opiant Pharmaceuticals: Opiant Pharmaceuticals (now part of Indivior) developed opioid overdose rescue therapeutics including nasal naloxone. It is a direct peer in the opioid overdose rescue / substance use disorder category that Orexo US is targeting.
• Collegium Pharmaceutical: Collegium Pharmaceutical is a US specialty pharma focused on responsible pain management and CNS therapeutics. It is a comparable peer in the US severe-disease and CNS specialty pharma space Orexo US is targeting.
• Alkermes: Alkermes is a specialty pharma with a proprietary drug delivery technology platform (e.g., NanoCrystal®, LinkeRx®) and a CNS-focused portfolio. It is the most directly comparable peer to Orexo's AmorphOX®-based, CNS/rescue-focused specialty pharma model.
• Emergent BioSolutions: Emergent BioSolutions is a direct competitor in the US opioid overdose rescue category through its NARCAN® (naloxone) nasal spray franchise. It is the most directly comparable peer given Orexo US's apparent focus on opioid overdose rescue and severe-disease rescue medications, and the fact that key US leader Lisa Moore came directly from Emergent's SUD/opioid franchise.
• Indivior: Indivior is a global specialty pharma focused on substance use disorder and addiction treatments. Its marketed SUBLOCADE® and other opioid-related products make it a direct peer in the SUD/rescue medication space Orexo US is pursuing.

Broad incumbents

• Hikma Pharmaceuticals: Hikma Pharmaceuticals is a multinational specialty and generic pharma with a substantial US presence in injectable, respiratory, and CNS categories. It is a broad incumbent comparable to Orexo US in the US specialty pharma space.
• Pfizer (post-Biohaven): Pfizer is a large multinational pharma that acquired Biohaven (former employer of Orexo US's CMO) and operates broadly in CNS and specialty pharma. It is a broad incumbent in the severe-disease and CNS spaces Orexo US is targeting.

Emerging players

• Catalent: Catalent is a global drug delivery and development services / CDMO with proprietary formulation technologies across multiple dosage forms. It is a comparable peer to Orexo's AmorphOX® drug delivery platform, though it operates primarily as a service provider rather than a product company.
• Biohaven Pharmaceuticals: Biohaven Pharmaceuticals (now part of Pfizer) developed migraine and CNS therapeutics and was the previous employer of Orexo US's CMO Edward Kim. It is a relevant peer in the CNS specialty pharma space where Orexo US's pipeline appears focused.
• Adapt Pharma (now part of Emergent): Adapt Pharma (acquired by Emergent BioSolutions) was the original US marketer of NARCAN® nasal spray for opioid overdose. It is a relevant peer in the opioid overdose rescue category that Orexo US is positioned to compete in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/orexo-us-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orexo US, Inc.